A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study

Science China Life Sciences

Volumn 62, Issue 3, 2019, Pages 369-380

  Li, Sheng ^a,b   Xu, Shengyong ^c   Li, Chenze ^a,b   Ran, Xiao ^a,b   Cui, Guanglin ^a,b   He, Mengying ^a,b   Miao, Kun ^a,b   Zhao, Chunxia ^a,b   Yan, Jiangtao ^a,b   Hui, Rutai ^d   Zhou, Ning ^a,b   Wang, Yan ^a,b   Jiang, Jiangang ^a,b   Zhang, Jing ^e   Wang, Daowen ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiologic Disorders   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d FUWAI HOSPITAL   (China)

^e Huazhong Cardiovascular Hospital   (China)

Author keywords

fulminant myocarditis; in hospital mortality; life support based comprehensive treatment regimen

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN;

ADULT; CLINICAL TRIAL; DRUG THERAPY; EXTRACORPOREAL OXYGENATION; FEMALE; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HOSPITAL MORTALITY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDITIS; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; DRUG THERAPY; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; GLUCOCORTICOIDS; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MYOCARDITIS; OUTCOME ASSESSMENT, HEALTH CARE; YOUNG ADULT;

EID: 85062784498     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-018-9501-9     Document Type: Article

References (34)

1. Althof, N., Goetzke, C.C., Kespohl, M., Voss, K., Heuser, A., Pinkert, S., Kaya, Z., Klingel, K., and Beling, A. (2018). The immunoproteasomespecific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol Med 10, 200–218.
2. Bjelakovic, B., Vukomanovic, V., and Jovic, M. (2016). Fulminant myocarditis in children successfully treated with high dose of methylprednisolone. Ind J Pediatr 83, 268–269.
3. Caforio A.L., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Helio T., Heymans S., Jahns R., et al. (2013). Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34, 2636–2648, 2648a-2648d.
4. Caforio, A.L.P., Malipiero, G., Marcolongo, R., and Iliceto, S. (2017). Myocarditis: a clinical overview. Curr Cardiol Rep 19, 63.
5. Chen H.S., Wang W., Wu S.N., and Liu J.P. (2013). Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 10, CD004471.
6. Diddle, J.W., Almodovar, M.C., Rajagopal, S.K., Rycus, P.T., and Thiagarajan, R.R. (2015). Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med 43, 1016–1025.
7. Drucker, N.A., Colan, S.D., Lewis, A.B., Beiser, A.S., Wessel, D.L., Takahashi, M., Baker, A.L., Perez-Atayde, A.R., and Newburger, J.W. (1994). Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89, 252–257.
8. Fung, G., Luo, H., Qiu, Y., Yang, D., and McManus, B. (2016). Myocarditis. Circ Res 118, 496–514.
9. Ginsberg, F., and Parrillo, J.E. (2013). Fulminant myocarditis. Crit Care Clin 29, 465–483.
10. Goland, S., Czer, L.S.C., Siegel, R.J., Tabak, S., Jordan, S., Luthringer, D., Mirocha, J., Coleman, B., Kass, R.M., and Trento, A. (2008). Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol 24, 571–574.
11. Gupta, S., Markham, D.W., Drazner, M.H., and Mammen, P.P. (2008). Fulminant myocarditis. Nat Rev Cardiol 5, 693–706.
12. Hafezi-Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F.P., Plumier, J. C., Rebsamen, M.C., Hsieh, C.M., Chui, D.S., Thomas, K.L., Prorock, A.J., et al. (2002). Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8, 473–479.
13. Hirasawa, H., Oda, S., Nakamura, M., Watanabe, E., Shiga, H., and Matsuda, K. (2012). Continuous hemodiafiltration with a cytokineadsorbing hemofilter for sepsis. Blood Purif 34, 164–170.
14. Isogai, T., Yasunaga, H., Matsui, H., Tanaka, H., Horiguchi, H., and Fushimi, K. (2015). Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Cardiac Failure 21, 391–397.
15. Kishimoto, C., Shioji, K., Hashimoto, T., Nonogi, H., Lee, J.D., Kato, S., Hiramitsu, S., and Morimoto, S. (2014). Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessels 29, 336–342.
16. Lazaros, G., Oikonomou, E., and Tousoulis, D. (2017). Established and novel treatment options in acute myocarditis, with or without heart failure. Expert Rev Cardiovasc Ther 15, 25–34.
17. Lim, H.S., Howell, N., and Ranasinghe, A. (2017). Extracorporeal life support: physiological concepts and clinical outcomes. J Cardiac Failure 23, 181–196.
18. Maisch, B., Ruppert, V., and Pankuweit, S. (2014). Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options. Curr Heart Fail Rep 11, 166–177.
19. McCarthy, R.E., Boehmer, J.P., Hruban, R.H., Hutchins, G.M., Kasper, E. K., Hare, J.M., and Baughman, K.L. (2000). Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342, 690–695.
20. Nakamura, H., Kunitsugu, I., Fukuda, K., Matsuzaki, M., and Sano, M. (2013). Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis. J Cardiol 61, 237–242.
21. Nakashima, H., Umeyama, Y., and Minami, K. (2013). Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support. Am J Case Rep 14, 116–119.
22. Okai, I., Inoue, K., Maruyama, M., Maruyama, S., Komatsu, K., Nishizawa, H., Okazaki, S., Fujiwara, Y., Sumiyoshi, M., and Daida, H. (2012). Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis. Heart Vessels 27, 639–642.
23. Pollack, A., Kontorovich, A.R., Fuster, V., and Dec, G.W. (2015). Viral myocarditis—diagnosis, treatment options and current controversies. Nat Rev Cardiol 12, 670–680.
24. Puymirat, E., Fagon, J.Y., Aegerter, P., Diehl, J.L., Monnier, A., Hauw-Berlemont, C., Boissier, F., Chatellier, G., Guidet, B., Danchin, N., et al. (2017). Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Fail 19, 192–200.
25. Rodrigues J.P.F., Caldas I.S., Goncalves R.V., Almeida L.A., Souza R.L.M., and Novaes R.D. (2017). S. mansoni-T. cruzi co-infection modulates arginase-1/iNOS expression, liver and heart disease in mice. Nitric Oxide 66, 43–52.
26. Rodríguez, A., Alvarez-Rocha, L., Sirvent, J.M., Zaragoza, R., Nieto, M., Arenzana, A., Luque, P., Socías, L., Martín, M., Navarro, D., et al. (2012). Recomendaciones del Grupo de Trabajo Enfermedades Infecciosas (GTEI) de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) y el Grupo de Estudio de Infecciones en el Paciente Crítico (GEIPC) de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica (SEIMC) para el diagnóstico y tratamiento de la gripe A/H1N1 en pacientes adultos graves hospitalizados en las Unidades de Cuidados Intensivos. Med Intensiva 36, 103–137.
27. Section of Precision Medical of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, and Working Group on Adult Myocarditis. (2017). Chinese expert consensus statement on clinical diagnosis and treatment of fulminant myocarditis in adults. Zhonghua Xin Xue Guan Bing Za Zhi 45, 742–752.
28. Shioji, K., Kishimoto, C., and Sasayama, S. (2001). Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis. Circ Res 89, 540–546.
29. Ting, M., Wang, C.H., Tsao, C.I., Huang, S.C., Chi, N.H., Chou, N.K., Chen, Y.S., and Wang, S.S. (2016). Heart transplantation under mechanical circulatory support for acute fulminant myocarditis with cardiogenic shock. Transplant Proc 48, 951–955.
30. Tschope C., Muller I., Xia Y., Savvatis K., Pappritz K., Pinkert S., Lassner D., Heimesaat M.M., Spillmann F., Miteva K., et al. (2017). NOD2 (nucleotide-binding oligomerization domain 2) is a major pathogenic mediator of Coxsackievirus B3-induced myocarditis. Circ Heart Fail 10, pii:e003870.
31. Ukimura, A., Izumi, T., Matsumori, A., and Clinical Research Committee on Myoc, A. (2010). A national survey on myocarditis associated with the 2009 influenza A (H1N1) pandemic in Japan. Circ J 74, 2193–2199.
32. Ukimura, A., Ooi, Y., Kanzaki, Y., Inomata, T., and Izumi, T. (2013). A national survey on myocarditis associated with influenza H1N1pdm2009 in the pandemic and postpandemic season in Japan. J Infect Chemother 19, 426–431.
33. Wang, D., Li, S., Jiang, J., Yan, J., Zhao, C., Wang, Y., Ma, Y., Zeng, H., Guo, X., Wang, H., et al. (2019). Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci 62, 187–202.
34. Zhang, L., Wei, T.T., Li, Y., Li, J., Fan, Y., Huang, F.Q., Cai, Y.Y., Ma, G., Liu, J.F., Chen, Q.Q., et al. (2018). Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases. Circulation 137, 1374–1390.